Wei Xu

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 383 citations · Full text

The First Approved Gene Therapy Product for Cancer Ad- <i>p53</i> (Gendicine): 12 Years in the Clinic

Weiwei Zhang, Longjiang Li, Dinggang Li et al. · Human Gene Therapy · 2018 · 297 citations

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 176 citations

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Andrea L.A. Wong, Ross A. Soo, Daniel S.W. Tan et al. · Annals of Oncology · 2015 · 166 citations

Refractory Solid Malignancies, Medicine, Cancer Biology +8

Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma

Cheng Fang, Danxia Zhu, Hua‐Jie Dong et al. · Annals of Hematology · 2011 · 163 citations

Lymphoid Neoplasia, Medicine, Immunology +11